利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

175 条记录 (耗时 0.022 秒)

    AMINO ANTHRACYCLINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
    51.
    发明授权
    AMINO ANTHRACYCLINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS 有权
    AMINOANTHRACYCLINONDERIVATE及其用于治疗淀粉样变性

    公开(公告)号：EP1062206B1

    公开(公告)日：2004-04-14

    申请号：EP99910304.7

    申请日：1999-02-25

    申请人： Pharmacia Italia S.p.A.

    发明人： BANDIERA, Tiziano ,  FANCELLI, Daniele ,  VARASI, Mario ,  CARUSO, Michele ,  LANSEN, Jacqueline ,  SUARATO, Antonino

    IPC分类号： C07D211/70 ,  C07D405/06 ,  A61K31/65

    CPC分类号： C07D405/06 ,  C07D211/70

    摘要： A compound of formula (1), wherein R1 represents hydrogen, hydroxy, a group of formula OR7, wherein R7 is C1-C6 alkyl, C2-C6 alkenyl; R2 represents hydrogen, hydroxy, diethylamino, piperidino, tetrahydropyridino or morpholino, and either R3, taken alone, represents hydrogen or hydroxy, and R4 and R5, taken alone, independently represent hydrogen, hydroxy or, taken together with the carbon atom, represent a carbonyl group; or R3 and R4, taken together, represent a group of formula (A), wherein R8 and R9 represent a C1-C6 alkyl and R5 represents hydrogen; R6 represents hydrogen or a phenyl group, optionally substituted by methyl, methoxy or halogen and the pharmaceutically acceptable salt thereof, is useful in the treatment of amyloidosis. Processes for the preparation and pharmaceutical compositions are also described.

    ABEO-ERGOLINE DERIVATIVES AS 5HT1A LIGANDS
    57.
    发明授权
    ABEO-ERGOLINE DERIVATIVES AS 5HT1A LIGANDS 失效
    ABEO麦角灵衍生物AS 5HT1A配体

    公开(公告)号：EP0708777B1

    公开(公告)日：2003-11-26

    申请号：EP95916653.9

    申请日：1995-04-13

    申请人： Pharmacia Italia S.p.A.

    发明人： MANTEGANI, Sergio ,  BANDIERA, Tiziano ,  BRAMBILLA, Enzo ,  CACCIA, Carla ,  CARFAGNA, Nicola

    IPC分类号： C07D487/06 ,  A61K31/40

    CPC分类号： C07D487/06

    摘要： There are provided compounds of formula (I), wherein R1 is a hydrogen, chlorine or bromine atom or a methyl, methylthio, hydroxy, cyano or carboxamido group; R2 is C1-C3 alkyl or an allyl group; R3 and R4 are independently a hydrogen atom, a C1-C5 alkyl group, a C3-C5 alkenyl group, a C5-C6 cycloalkyl C1-C3 alkyl group, a phenyl-C1-C3 alkyl, a phenyl -C3-C5 alkenyl or phenyl group: which groups are optionally substituted by C1-C3 alkyl, C1-C3 alkoxy, trifluoromethyl, hydroxy or amino group; or a group of formula (a), wherein R6 is hydrogen atom or a C1-C3 alkyl group and R7 is a phenyl group, a substituted phenyl group as described above or a heterocyclic ring, R5 is a hydrogen or bromine atom or an organic residue and R is H or an organic residue, or a pharmaceutically acceptable salt thereof. A process for their preparation and the pharmaceutical compositions comprising them are also provided.